Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Nasser Alhajj, Chin Fei Chee, Tin Wui Wong, Noorsaadah Abd Rahman, Noor Hayaty Abu Kasim & Paolo Colombo. (2018) Lung cancer: active therapeutic targeting and inhalational nanoproduct design. Expert Opinion on Drug Delivery 15:12, pages 1223-1247.
Read now
Read now
Diane E Milenic, Kwamena E Baidoo, Young-Seung Kim & Martin W Brechbiel. (2015) Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. mAbs 7:1, pages 255-264.
Read now
Read now
Yujiong Wang, Guangcun Deng, Xiaoming Liu & William C Cho. (2013) Monoclonal antibodies in lung cancer. Expert Opinion on Biological Therapy 13:2, pages 209-226.
Read now
Read now
Nitin Patil, Mohammed Abba & Heike Allgayer. (2012) Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics: Targets and Therapy 6, pages 221-231.
Read now
Read now
Uwe Wollina. (2012)
Cetuximab in non-melanoma skin cancer. Expert Opinion on Biological Therapy 12:7, pages 949-956.
Read now
Read now
Chris Hemmings, Amy Broomfield, Elaine Bean, Martin Whitehead & Desmond Yip. (2009) Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. Pathology 41:4, pages 356-360.
Read now
Read now
Bruno Vincenzi, Gaia Schiavon, Marianna Silletta, Daniele Santini & Giuseppe Tonini. (2006) The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. Expert Opinion on Emerging Drugs 11:4, pages 665-683.
Read now
Read now
Mario Scartozzi, Chiara Pierantoni, Rossana Berardi, Michela Squadroni & Stefano Cascinu. (2006) Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. Expert Opinion on Therapeutic Targets 10:2, pages 281-287.
Read now
Read now
Ekatherine Asatiani & Edward P Gelmann. (2005) Targeted therapies for prostate cancer. Expert Opinion on Therapeutic Targets 9:2, pages 283-298.
Read now
Read now
Articles from other publishers (42)
Yu-Chen Yang, Yu Zhu, Si-Jia Sun, Can-Jun Zhao, Yang Bai, Jin Wang & Li-Tian Ma. (2023) ROS regulation in gliomas: implications for treatment strategies. Frontiers in Immunology 14.
Crossref
Crossref
Faizah Farooq, Asif Amin, Umer Majeed Wani, Asif Lone & Raies A. Qadri. (2023) Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance. Journal of Cellular Physiology 238:8, pages 1651-1669.
Crossref
Crossref
Kehong Li, Wenqi Fan, Jingxuan Yan, Jing Wang, Peng Zhao, Wei Liao, Yuchuan Yang, Xia Yang, Hongyuan Wei & Yue Chen. (2023) Comparative cytotoxicity of 177Lu on various lung cancer cells and in vivo targeting of 177Lu-labeled cetuximab. Journal of Radioanalytical and Nuclear Chemistry 332:6, pages 2093-2102.
Crossref
Crossref
Anna Mestre Borras, Charles Dahlsson Leitao, Stefan Ståhl & John Löfblom. (2023) Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting. New Biotechnology 73, pages 9-18.
Crossref
Crossref
Mei Lan Tan, Jia Wen Yeap & Azlinah Matawali. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
32
.
Romana Moench, Martin Gasser, Karol Nawalaniec, Tanja Grimmig, Amrendra K. Ajay, Larissa Camila Ribeiro de Souza, Minghua Cao, Yueming Luo, Petra Hoegger, Carmen M. Ribas, Jurandir M. Ribas-Filho, Osvaldo Malafaia, Reinhard Lissner, Li-Li Hsiao & Ana Maria Waaga-Gasser. (2022) Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer. Oncotarget 13:1, pages 1140-1152.
Crossref
Crossref
Helen Damerow, Xia Cheng, Valeska von Kiedrowski, Ralf Schirrmacher, Björn Wängler, Gert Fricker & Carmen Wängler. (2022) Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?. Pharmaceutics 14:10, pages 2114.
Crossref
Crossref
Rocío García-Vázquez, Umberto Battisti & Matthias Herth. (2022) Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging. Pharmaceuticals 15:6, pages 685.
Crossref
Crossref
Wei Liu, Kehong Li, Hao Deng, Jing Wang, Peng Zhao, Wei Liao, Liangang Zhuo, Hongyuan Wei, Xia Yang & Yue Chen. (2022) In vitro and in vivo evaluation of a novel anti-EGFR antibody labeled with 89Zr and 177Lu. Journal of Radioanalytical and Nuclear Chemistry 331:2, pages 747-754.
Crossref
Crossref
Shujing Yue, Yifan Zhang, Yaohua Wei, Rainer Haag, Huanli Sun & Zhiyuan Zhong. (2021) Cetuximab–Polymersome–Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers. Biomacromolecules 23:1, pages 100-111.
Crossref
Crossref
Svenja Siemer, Tobias A. Bauer, Paul Scholz, Christina Breder, Federico Fenaroli, Gregory Harms, Dimo Dietrich, Jörn Dietrich, Christine Rosenauer, Matthias Barz, Sven Becker, Sebastian Strieth, Christoph Reinhardt, Torsten Fauth, Jan Hagemann & Roland H. Stauber. (2021) Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin. ACS Nano 15:11, pages 18541-18556.
Crossref
Crossref
Christian H. Klein, Dina C. Truxius, Holger A. Vogel, Jana Harizanova, Sandip Murarka, Pablo Martín-Gago & Philippe I.H. Bastiaens. (2019) PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. International Journal of Cancer 144:4, pages 767-776.
Crossref
Crossref
P.-S. Bellaye, M. Moreau, O. Raguin, A. Oudot, C. Bernhard, J.-M. Vrigneaud, L. Dumont, D. Vandroux, F. Denat, A. Cochet, F. Brunotte & B. Collin. (2018) Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models. Clinical and Translational Oncology 20:12, pages 1557-1570.
Crossref
Crossref
E. Johanna L. Stéen, Patricia E. Edem, Kamilla Nørregaard, Jesper T. Jørgensen, Vladimir Shalgunov, Andreas Kjaer & Matthias M. Herth. (2018) Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. Biomaterials 179, pages 209-245.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Corinna Bingel, Emily Koeneke, Johannes Ridinger, Annika Bittmann, Martin Sill, Heike Peterziel, Jagoda K Wrobel, Inga Rettig, Till Milde, Uta Fernekorn, Frank Weise, Andreas Schober, Olaf Witt & Ina Oehme. (2017) Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. Cell Death & Disease 8:8, pages e3013-e3013.
Crossref
Crossref
Romana Moench, Tanja Grimmig, Vinicius Kannen, Sudipta Tripathi, Marc Faber, Eva-Maria Moll, Anil Chandraker, Reinhard Lissner, Christoph-Thomas Germer, Ana Maria Waaga-Gasser & Martin Gasser. (2016) Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget 7:42, pages 68749-68767.
Crossref
Crossref
Nan-xiang Chen, Lei Chen, Jia-ling Wang, Jin-yuan Wang, Fang Yan, Lin Ma & Xin-xin Zhang. (2016) A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. Japanese Journal of Clinical Oncology 46:8, pages 727-734.
Crossref
Crossref
Anna Leonidova, Christian Foerster, Kristof Zarschler, Maik Schubert, Hans-Jürgen Pietzsch, Jörg Steinbach, Ralf Bergmann, Nils Metzler-Nolte, Holger Stephan & Gilles Gasser. (2015)
In vivo
demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system
. Chemical Science 6:10, pages 5601-5616.
Crossref
Crossref
MING QIAN, DONGHUA QIAN, HONGYU JING, YANG LI, CHENGYUAN MA & YANMIN ZHOU. (2014) Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncology Reports 32:4, pages 1681-1688.
Crossref
Crossref
Alena Wiegandt & Bernd Meyer. (2014)
Unambiguous Characterization of
N
-Glycans of Monoclonal Antibody Cetuximab by Integration of LC-MS/MS and
1
H NMR Spectroscopy
. Analytical Chemistry 86:10, pages 4807-4814.
Crossref
Crossref
Wiebke Sihver, Jens Pietzsch, Mechthild Krause, Michael Baumann, Jörg Steinbach & Hans-Jürgen Pietzsch. (2014) Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. Pharmaceuticals 7:3, pages 311-338.
Crossref
Crossref
Helen L. Evans, Quang-Dé Nguyen, Laurence S. Carroll, Maciej Kaliszczak, Frazer J. Twyman, Alan C. Spivey & Eric O. Aboagye. (2014)
A bioorthogonal
68
Ga-labelling strategy for rapid in vivo imaging
. Chem. Commun. 50:67, pages 9557-9560.
Crossref
Crossref
Shuang Bai, Rong Deng, Hong Xiang, Manish Gupta, Luna Musib, Banmeet Anand & Bert Lum. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
585
624
.
Janet L. Markman, Arthur Rekechenetskiy, Eggehard Holler & Julia Y. Ljubimova. (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Advanced Drug Delivery Reviews 65:13-14, pages 1866-1879.
Crossref
Crossref
Christoph Wierling, Alexander Kühn, Hendrik Hache, Andriani Daskalaki, Elisabeth Maschke-Dutz, Svetlana Peycheva, Jian Li, Ralf Herwig & Hans Lehrach. (2012) Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 746:2, pages 163-170.
Crossref
Crossref
Cesare Gridelli & Antonio Rossi. 2012. Lung Cancer Therapy Annual 7. Lung Cancer Therapy Annual 7
59
74
.
Roberto Bianco, Teresa Gelardi, Sonia Garofalo, Roberta Rosa & Giampaolo Tortora. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
407
436
.
Cesare Gridelli, Paolo Maione, Marianna Luciana Ferrara & Antonio Rossi. (2009) Cetuximab and Other Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer. The Oncologist 14:6, pages 601-611.
Crossref
Crossref
Giulio Rossi, Giuseppe PelosiPaolo Graziano, Mattia Barbareschi & Mauro Papotti. (2009) Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology 17:3, pages 206-218.
Crossref
Crossref
Mu Zhang, Weiyang Tao, Shangha Pan, Xueying Sun & Hongchi Jiang. (2009) Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anti-Cancer Drugs 20:5, pages 355-363.
Crossref
Crossref
Jamil Hantash, Mary Smidt & Ronald R. Bowsher. (2009) The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in human serum. Analytical Methods 1:2, pages 144.
Crossref
Crossref
Bruno Vincenzi, Gaia Schiavon, Marianna Silletta, Daniele Santini & Giuseppe Tonini. (2008) The biological properties of cetuximab. Critical Reviews in Oncology/Hematology 68:2, pages 93-106.
Crossref
Crossref
Kimberly A. Bauer, Scott Hammerman, Bernardo Rapoport & Mario E. Lacouture. (2008) Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials. Clinical Colorectal Cancer 7:5, pages 309-314.
Crossref
Crossref
Timothy Craig Allen, Anna Sienko & Philip T. Cagle. 2008. Molecular Pathology of Lung Diseases. Molecular Pathology of Lung Diseases
226
232
.
Philip T. Cagle, Jaishree Jagirdar & Helmut H. Popper. 2008. Dail and Hammar’s Pulmonary Pathology. Dail and Hammar’s Pulmonary Pathology
47
157
.
G Galizia, E Lieto, F De Vita, M Orditura, P Castellano, T Troiani, V Imperatore & F Ciardiello. (2007) Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26:25, pages 3654-3660.
Crossref
Crossref
Fion L. Sung, Ronald T. K. Pang, Brigette B. Y. Ma, May M. L. Lee, Shuk Man Chow, Terence C. W. Poon & Anthony T. C. Chan. (2006) Pharmacoproteomics Study of Cetuximab in Nasopharyngeal Carcinoma. Journal of Proteome Research 5:12, pages 3260-3267.
Crossref
Crossref
Antonio Rossi, Paolo Maione & Cesare Gridelli. (2006) Cetuximab in advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology 59:2, pages 139-149.
Crossref
Crossref
Vittorio Gebbia, Salvatore Del Prete, Nicoló Borsellino, Francesco Ferraú, Paolo Tralongo, Francesco Verderame, Vita Leonardi, Elena Capasso, Evaristo Maiello, Roberto Bordonaro, Sergio Stinco, Biagio Agostara & Carlo Barone. (2006) Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience. Clinical Colorectal Cancer 5:6, pages 422-428.
Crossref
Crossref
Anthony T.C. ChanMow-Ming HsuBoon C. GohEdwin P. HuiTsang-Wu LiuMichael J. MillwardRuey-Long HongJacqueline Whang-PengBrigette B.Y. MaKa F. ToMatthias MueserNadia AmellalXiao LinAlex Y. Chang. (2005) Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. Journal of Clinical Oncology 23:15, pages 3568-3576.
Crossref
Crossref
M.P. Morelli, T. Cascone, T. Troiani, F. De Vita, M. Orditura, G. Laus, S.G. Eckhardt, S. Pepe, G. Tortora & F. Ciardiello. (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology 16, pages iv61-iv68.
Crossref
Crossref